November

we were included in the 2019 Zhejiang Province Pharmaceutical Intelligent Factory List.

September

Huahai and China Pharmaceutical University will jointly build a research and development center for innovative drugs and high-end preparations.

July

we were awarded two important honors by the China Chamber of Commerce for the Import and Export of Medicines and health products: 2019 Award for Excellent suppliers & Partners in International Market; 2019 Award for Leading Formulation supplier.

June

we won the title of "Top 100 Pharmaceutical Industry in China" and "Top 20 R&d companies of China Pharmaceutical Group".

May

our first anti-infective product was marketed in China.

April

a delegation of Medical representatives from the Nigerian government visited Huhai.

March

according to IQVIA's annual list of top 10 fast-growing Generic drugs companies in the US in 2018, Solco Healthcare, a sales company affiliated to Huahai US won the first place in terms of the growth rate of prescription volume of generic drugs in the US, and also entered the top 10 in terms of sales growth of generic drugs in the US.

February

China Chronic Disease Brand Medical College and Huahai signed a strategic cooperation framework agreement.

January

Huahai Pharmaceutical Sales Company held a housewarming celebration.

June

Established an entity in Munich, Germany, Huahai (Europe) Pharm Co., Ltd.

May

we were approved by the FDA of the US for the preparation Clopidogrel Hydrogen Sulfate Tablets.

February 23

we were successfully rated as a “Green Factory” in the second batch of green manufacturing list released by the Ministry of Industry and Information Technology of the P.R.C., including green factories, green design products, green parks, and demonstration enterprises for green supply chain management.

February

we enjoyed two programs in the special programs of national key technologies for “Great Creation and Development of New Drugs” in 2017.

February

we were rated as an enterprise with national advantages in intellectual property.

February 28

we ranked first among the top 20 enterprises for exporting western medicine preparation in 2017 released by the China Chamber of Commerce for Import & Export of Medicines & Health Products.

January 19

Huahai (Japan) Co., Ltd. was officially put into operation to further promote the global layout.

January 17

we were listed as “Demonstration Enterprises for Innovative Development of Processing Trade in Zhejiang Province”.

November

we started to construct Linhai International Pharmaceutical Town (Technological Industry Park of Huahai Pharmaceutical Co., Ltd.).

October 11

we signed an agreement for strategic cooperation with Enze Medical.

September 2

we ranked as one of the top 100 enterprises in the pharmaceutical industry of China in 2016.

September 1

we invested in shares of Eutilex in Korea.

July

Huabo, our wholly-owned subsidiary, received the Approval for Clinical Trials of Drugs issued by the State Food and Drug Administration of the P.R.C. for recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection.

June

we pioneered to successfully challenge the patent of developing original drugs in the US by mean of Paroxetine Mesylate Capsule.

May

we were approved by the FDA of the US for Telmisartan Tablets.

May

we were approved by the FDA of the US for Duloxetine Hydrochloride Enteric Capsules.

April

we were approved by the FDA of the US for Olmesartan Medoxomil and Hydrochlorothiazide Tablets.

February

we ranked first among the top 100 enterprises of China for exporting pharmaceutical products in 2016 released by China Chamber of Commerce for Import & Export of Medicines & Health Products.

December

our wholly-owned subsidiary Huahai US Inc. acquired the Charlotte factory.

November

we were approved for clinical trials of Duloxetine Hydrochloride Enteric Capsules.

November

we were granted with an approval number from the FDA of the US for Doxycycline Hydrochloride Sustained-Release Tablets.

November 28

we launched a program for organizational design and transformation.

May 18

we were successfully reviewed by the Ministry of Industry and Information Technology of the P.R.C. for the “two-izations” integration management system.

March 15

our trade union won the title of “Home of National Model Workers”.

March 1

Huahai US Inc. signed an agreement for strategic cooperation with LP Pharma and Zhejiang Pharmaceutical Co., Ltd.

January 20

we officially established the Advanced Analysis Technology Center (CEMAT).

January 18

we won the second prize of National Science and Technology Progress Award for “R&D and Industrialization of Refining and Crystallization Technologies for High-end Pharmaceutical Products”.

December

we ranked as “Top 100 Enterprises for Technological Innovation in Zhejiang Province in 2015”.

December 1

we won the 2015 Most Powerful Brand Enterprise Award.

November,

we were listed as an enterprise in the second batch for pilot cultivation of “three well-known programs” of Zhejiang Province.

November 30

we were awarded “Star for Internationalization in the 12th Five-Year Plan” in the pharmaceutical industry of China.

October 28

Chen Baohua, general manager of Huahai Pharmaceutical Co., Ltd., was elected as “Figures of China's Pharmaceutical Economy in 2015”.

September

we were granted with an approval number from the FDA of the US for our preparation Escitalopram Oxalate Tablets.

September 29

we established the EHS Management System Committee and held the first meeting.

August 18

Zhejiang Apeloa Pharmaceutical signed a framework agreement for strategic cooperation with Huahai (USA) Company.

August

we ranked as “Top 100 Well-known Pharmaceutical Enterprises in China”.

August

we ranked as “Top 10 Valuable Pharmaceutical Companies Listed in 2015”.

August

we were approved for clinical trials for I, II, and III of our innovative drug Hydroxypiperone Hydrochloride developed with the Academy of Military Medical Sciences.

July 12

we were listed again as “Top 100 Enterprises in the Pharmaceutical Industry of China in 2014” at the 32nd National Pharmaceutical Industry Information Conference.

June

we were approved by the FDA of the US for our new antidepressant drug Bupropion Hydrochloride Sustained-Release Tablets.

June

we were granted with an approval number from the FDA of the US for our preparation Valsartan Tablets.

June 28

Huahai (USA) Company signed a framework agreement for strategic cooperation with Shouguang Fukang Pharmaceutical Co., Ltd.

May

we were granted with an approval number from the FDA of the US for our preparation Levetiracetam Extended-Release Tablets.

May

we won the first prize of the 2014 Tianjin Science & Technology Progress Award for the program “R&D and industrialization of refining and crystallization technologies for high-end pharmaceutical products” jointly completed with Tianjin University, Shenzhen Huarun Jiuxin Pharmaceutical Co., Ltd., Xi’an Lijun Pharmaceutical Co., Ltd. and National Institutes for Food and Drug Control.

April

we ranked as “Top 20 Enterprises of China for Export of Western Medicine API in 2014” and “Top 20 Enterprises of China for Export of Generic Medicine in 2014”.

April

we ranked as “Zhejiang High-tech Enterprise in 2014”.

April 29

we increased capital to hold Huzhou Changxing Pharmaceutical CO., Ltd.

March 2

Shanghai Huaota Biopharm Co., Ltd. officially started to construct the pilot platform for the research and development of biological products.

January

our first program with ONCOBIOLOGICS company in the US was successfully put into trial production in Shanghai Huaota Biopharm Co., Ltd.

January 22

we cooperated with Liu Changxiao, academician of the Chinese Academy of Engineering, to build an academician workstation.

January 21–22

we successfully transferred the technologies for the first program “Class-1.1 new antidepressant drug Hydroxypiperone Hydrochloride Tablets” under the cooperation with Academy of Military Medical Sciences.

January 14

we set up “Research Institute for Environmental Protection and Engineering” and “Postdoctoral Workstation for Environmental Protection” with Tongji University.

January 9

our program “Development and Industrialization of Green Key Technologies for Anti-Hypertension Sartan Drugs” submitted jointly with Shanghai Institute of Pharmaceutical Industry and Changzhou Siyao Pharmaceutical Co., Ltd. won the second prize of National Science and Technology Progress Award.

January 1

our Pregabalin Capsules, the first product in the program “R&D in one place and declaration in three places”, was successfully launched in Germany.

December

we were successfully accepted for “Building of the Innovation Capacity of National Accreditation Enterprise Technology Center”.

December

we ranked the “Top 100 Enterprises for Highly-technical Innovation in Zhejiang Province in 2014”.

December 26

we signed the Agreement for Strategic Enterprise-University-Research Cooperation between Universities and Enterprises with Dali University.

November

we were approved for the ANDA of anti-depressant drug Paroxetine Hydrochloride Tablets.

November 26

our “Therapeutic Biopharmaceutical Innovation Team” was rated as the leading team for innovation and entrepreneurship in Zhejiang Province in 2014.

November 20

the executives from 18 pharmaceutical giants in the world, including Novartis, Merck and Sanofi arrived at Huahai, visiting our workshop of preparation for export. They had a face-to-face exchange with Chen Baohua, general manager, Chen Qimao, deputy general manager, and Wang Hai, senior vice president of Huahai US Inc.

November 18

the meeting for industry-university-research cooperation between Taizhou Municipal Government and China Pharmaceutical University was held in Nanjing. Tong Jianxin, chairman of Huahai Pharmaceutical Co., Ltd., attended the meeting and made a speech. Huahai Pharmaceutical Co., Ltd. and China Pharmaceutical University signed an agreement for the five-year education development fund.

November 10

our Lisinopril Tablet API was approved by the FDA of the US for self-supply, indicating that we could use self-produced APIs for preparation.

October 30

Huahai Pharmaceutical Co., Ltd. and Tasly signed the Framework Agreement for Strategic Cooperation between Tasly Pharmaceutical Group Co., Ltd. and Huahai US Inc.

September 2

College of Pharmaceutical Science of Zhejiang University of Technology and Huahai Pharmaceutical Co., Ltd. jointly held a ceremony to launch the training base, with the education base for practice outside the College of Pharmaceutical Science officially settled in Huahai.

September 2

Tianjin Pharmaceutical Group Co., Ltd. signed a framework agreement for strategic cooperation with Huahai Pharmaceutical Co., Ltd.

August 7

our Metoprolol Succinate and Pioglitazone Hydrochloride APIs were successfully registered in the European Union and granted with the CEP/COS certificate.

June 29

we were listed “Top 100 Chinese Pharmaceutical Industries” in 2013.

June

Huahai Technology Apartment was officially put into service.

May

we were granted with the CEP certificate for Quinapril Hydrochloride API, being a pharmaceutical company in the first batch to receive this certificate in the world.

May

we successfully ranked as a pilot enterprise for the “two- izations” integrated management system implementing standard of the Ministry of Industry and Information Technology of the People’s Republic of China.

May

our preparations Irbesartan and Hydrochlorothiazide Tablets ANDA were approved by the FDA of the US. The high-density polyethylene bottles and polypropylene caps produced by our controlled subsidiary Zhejiang Huahai Pharmaceutical Packaging Products Co., Ltd. were successfully registered and filed by the FDA, and the ANDA of the package of the preparation product used for US standards was approved by the FDA.

May 23

Huahai Pharmaceutical Chuanan Branch was certified with zero defects by the FDA of the US.

March 22

Zhejiang Huahai Pharmaceutical Packaging Products Co., Ltd., one of our subsidiaries, was officially put into operation, further expanding our business sectors and industrial chains.

March 31

our provincial-level corporate research institute was acknowledged for acceptance by the experts from Zhejiang Provincial Science & Technology Department and Taizhou Municipal Science & Technology Bureau.

March 10

our state-level industrialization project – “International Certification for Pharmaceutical Preparations and Preparations for Export of Annual Output of 10 Billion Tablets (Pills)” was accepted for completion.

November 5

we were successfully certified in compliance with the updated GMP in China.

September 10

we were officially approved to produce the newly-developed anti-AIDS drug Efavirenz Tablets, pioneering to produce efavirenz tablets in China.

August 9

our five API products of Benazepril Tablets, nine preparation products such as Lamotrigine Controlled-Release Tablets and production line with annual production capacity of 10 billion tablets were certified with zero defects by the FDA of the US.

July

we ranked the top 100 companies in the pharmaceutical industry of China in 2012.

July

Huahai Pharmaceutical (USA) Zhejiang International Science & Technology Cooperation Base was listed as an International Science & Technology Cooperation Base in Zhejiang Province.

June 3

our proprietary Risperidone Dispersible Tablets in chemical category 5 were approved for drug registration by the State Food and Drug Administration of China.

May 6

we officially signed an agreement for strategic cooperation in biological medicine with ONCOBIOLOGICS, a biopharmaceutical company in the US.

March

Shanghai SynCores Technologies, Inc., our wholly-owned subsidiary, won the title of “National High-Tech Enterprise of China”.

January

we won the title of “Entrepreneurship and Innovation Base for Zhejiang Overseas High-level Talents”.

January 28

Huahai Pharmaceutical Co., Ltd. signed an agreement for strategic cooperation with Zhejiang Provincial Academy of Environmental Sciences.

September

our "Building the Capacity for Internationalization of Preparations" was listed in the "Special Programs for Development of Generic Drugs in 2012" jointly sponsored by the National Development and Reform Commission, Ministry of Finance, Ministry of Health, Ministry of Industry and Information Technology of the P.R.C.

September

Chen Baohua, Chairman and General Manager, was listed as an "Outstanding Entrepreneur for Environmental Protection" by the Ministry of Environmental Protection of the P.R.C.

September

we ranked as one of the top 20 most competitive listed pharmaceutical companies in 2012, being the only pharmaceutical company honored in Zhejiang Province.

September 17

we were successfully certified in compliance with the national GMP of China for the 3.3 billion tablets production line at the initial phase of the 10 billion a/c preparation workshop.

August 21

our preparation products were successfully approved to get into the Russian market.

June 27

our Efavirenz Tablets were certified with zero defects in compliance with the GMP in Brazil, starting a new chapter for Huahai's preparation products to get available in the South American market.

April

our figurative mark " " was affirmed as "China Famous Trademark" by the State Administration for Industry and Commerce of the P.R.C.

April

we won the title of "Pilot Enterprise of China Medicines' International Pharmaceutical Certification".

March

our technical patent "One-step Preparation Method for Assembly of Paroxetine Hydrochloride's Polymorph A Crystal Molecules" won "China's excellent patent award".

March 13

we acquired Solco Healthcare U.S., a well-known pharmaceutical distributor in the USA.

February 24

we fulfilled the first "Zhejiang University - Huahai" seminar for the courses of pharmaceutical postgraduates as scheduled.

July

Chen Baohua arrived in the USA to attend the Zhejiang–New Jersey Investment and Trade Fair.

June

we were rated as an advanced unit of Zhejiang Province for energy saving and cost reducing as per the "11th Five-year Plan".

May 12

we won the first prize of the award for scientific and technological achievements thanks to the transformation of ACEI green synthetic technologies.

April

our solid preparation production line and the production sites of API in Xunqiao and South Sichuan were successfully certified by the FDA of the US on site with zero defects, and five preparation products and eight API products won the "Permit" to be available in the American market.

March

we completed the conceptual design for the first sterile preparation workshop.

February

our initiatives were incorporated as a typical case of Zhejiang Province for harmonious relations with employees.

February

we signed a strategic agreement with Novartis International Pharmaceutical Co., Ltd. to further promote our internationalization process with pharmaceutical giants in the world.

October

we set up the Research Institute of Huahai Pharmaceutical Co., Ltd., and formally incorporated it into the "Plan of Zhejiang Province for Building Corporate Research Institutes in 2010", which served as a provincial corporate institute.

October 15

we were successfully reviewed by experts for our "12th Five-year Plan" and a long-term plan for development in Hangzhou.

September 26

our brand-new anti-hypertensive API was rated as a provincial brand-new product.

September 19

we were approved to set up the state-level post-doctoral research workstation.

March 24

we were accepted for safety standardization of Zhejiang Province.

February

we were listed in the national program for the hydrogenation technique of Ramipril.

December 28

we were rated as "Famous Trademarks of Zhejiang Province" for our figurative mark.

November

we were rated as a Demonstration Enterprise for Patents in Zhejiang Province.

November

we were listed in the special programs of the Ministry of Industry and Information Technology of the P.R.C. for innovation of industrial technologies in 2009 thanks to "Technological innovation of Losartan, a brand-new anti-hypertensive drug".

November

we were listed in the key scientific and technological programs and theme-prioritized programs for "Technical development and EU listing of Donepezil Hydrochloride Tablets".

October 12

we were rated as a candidate for Zhejiang Science and Technology Award thanks to the R&D of Nevirapine.

September 16

we officially put Shanghai R&D Center of Huahai US Inc. put into operation.

September

we were rated as one of the technical innovation team for key enterprises of Zhejiang Province in the first batch, serving as one of the teams in the first batch for R&D and innovation of API and preparation in key enterprises.

July 7

we approved the incentive plan for stock option by the Board of Directors.

January 9

we won the second prize of National Science and Technology Progress Award for the achievements made in "Development and Industrialization of ACEIs Related Key Technologies".

October 13

we started to fully implement the C-TPAT Manual.

October

our Technical Center was jointly rated as the "Technical Center for State-level Enterprises" by the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation of the P.R.C.

October

we officially put the API R&D Building with more than RMB 50 million into service in the Headquarters.

August

we completed the main buildings for No. 2 Sub-factory in Huahai South Sichuan Industrial Zone.

February

we were successfully certified in compliance with the OHSAS18001 system (Occupation Health Safety Management System), and granted with a certificate.

February 26

we launched to build enterprise culture.

February 1

we were successfully certified in compliance with the OHSAS18001 system.

November

we were rated as the "Enterprises for Pilot Innovation in Zhejiang Province".

November 1

we were successfully audited by the authorities from Germany for our Donepezil API and solid preparation workshop.

June 25

we were successfully certified by the USA FDA with zero defects for the Nevirapine preparation and its production line.

May 29

we donated RMB 25 million to Linhai Charity Foundation for the sponsorship fund.

March 27

we welcomed the experts from the USA FDA certification to hold the first meeting, starting the two-week audit for quality.

December 2

Huahai US Inc. submitted the ANDA for Nevirapine to the FDA of the USA.

August

our subsidiary "Linhai South China Chemical Co., Ltd." was successfully certified in compliance with the ISO9000 Quality Management System.

March 28

we held a ceremony for laying the foundation of Huahai Pharmaceutical (Xunqiao) New Preparation Plant.

November 23

we welcomed Xia Baolong, Deputy Secretary of Zhejiang Provincial Committee of CPC, to visit us.

October

we won the title of "National Environment Friendly Enterprise".

July

we put No. 1 Sub-factory in Huahai South Sichuan Industrial Zone into commission and operation.

June

we set up a subsidiary "Shanghai SynCores Technologies, Inc.” in Shanghai Zhangjiang High-Tech Park.

April 1

we were approved to set up the "Post-Doctoral Research Workshop of Huahai Pharmaceutical Co., Ltd.".

January

we set up No. 1 Sub-factory in Huahai South Sichuan Industrial Zone.

November

we were listed in the "National Program of China for High-tech Research and Development " (the "863" program) for our Nelfinavir, anti-AIDS drug.

October

we set up a wholly-owned subsidiary "Huahai US Inc." in New Jersey known as the "Drug Valley of the United States".

July

we set up a wholly-owned subsidiary "Zhejiang Huahai Pharmaceutical Sales Co., Ltd." in Hangzhou.

June

we set up a subsidiary "Shanghai Aobo Pharmtech, Inc., Ltd." in Shanghai Zhangjiang High-Tech Park.

June

we set up a subsidiary "Shanghai Shuanghua Biomedical Technology Development Co., Ltd." in Shanghai Zhangjiang High-Tech Park.

June 8

we welcomed Xi Jinping, a member of CPC Central Committee and Secretary of Zhejiang Provincial Committee of CPC, to visit us.

April 28

we were successfully certified by the USA FDA with zero defects for our Lisinopril condensate, a kind of API products.

December 19

we set up the Joint Research Center of Huahai Pharmaceutical Co., Ltd.–Shanghai Institute of Pharmaceutical Chemistry.

September 25

we held a mobilization meeting for building the performance appraisal management system to start the appraisal system.

July 22

we held a ceremony for laying the foundation of South Sichuan Industry Park of Huahai Pharmaceutical Co., Ltd. of Zhejiang Chemical API Base.

June 13

we officially set up a Committee for the Communist Party of China in Zhejiang Huahai Pharmaceutical Co., Ltd.

March 4

we were successfully listed in the A-share market of Shanghai Stock Exchange.

December

we were successfully certified in compliance with the ISO14001 Environment Management System.

September

we were listed in the "National Program for Technological Innovation" for our Nelfinavir, anti-AIDS pharmaceutic preparation.

August

we were successfully certified in compliance with the national GMP for the first solid preparation workshop (for tablets and capsules) with more than RMB 5 million.

July

we formally put the building complex with more than RMB 9 million into service.

July

we held a mobilization meeting for building enterprise culture.

July

we were approved for the general layout plan of Huahai South Sichuan Industrial Zone, a national base for the chemical API base.

February

we ranked as one of the top 500 private enterprises in China.

November

we welcomed Chen Muhua, the former Vice Chairman of the NPC Standing Committee of the P.R.C., to visit us.

September

we set up the Joint Research Center of Huahai Pharmaceutical Co., Ltd.–Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

March

we were rated as the "Hi-tech R&D Center of Zhejiang Province".

February

we set up our wholly-owned subsidiary "Zhejiang Huahai Import & Export Co., Ltd.".

February

we fully renamed as "Zhejiang Huahai Pharmaceutical Co., Ltd.".

August 2000

we welcomed Zhang Dejiang, Secretary of Zhejiang Provincial Committee of CPC, to visit us.

July 2000

we were successfully certified in compliance with the national GMP for Rebamipide, our API, to transform from a pharmaceutical chemical enterprise to a pharmaceutical enterprise.

May 2000

we welcomed Bu He, Vice Chairman of the NPC Standing Committee of the P.R.C., to visit us.

January 2000

we won the title of "Top 500 Private Enterprises in China" for the first time.

2000

we completed the first building for preparations, and successfully certified in compliance with the GMP.

November 1999

we increased the registered capital and renamed as "Zhejiang Huahai Pharmaceutical (Group) Co., Ltd."

January 1999

we renamed as "Zhejiang Huahai Pharmaceutical Co., Ltd."

1998

we set up the trade union for Zhejiang Huahai Pharmaceutical Chemical Co., Ltd. 1999年1月 更名为“浙江华海药业有限公司”

August 1998

we set up the first wholly-owned subsidiary "Linhai South China Chemical Co., Ltd.".

April 1997

we increased the registered capital and renamed as "Zhejiang Huahai Pharmaceutical Chemical Co., Ltd."

December 1997

we pioneered to be successfully certified in compliance with that the ISO9002 Quality Management System in Linhai City.

July 1995

we restructured, increased the registered capital, and renamed as "Linhai Huahai Chemical Co., Ltd."

July 1995

we restructured, increased the registered capital, and renamed as "Linhai Huahai Chemical Co., Ltd."

December 1991

we increased the registered capital and renamed as "Linhai Huahai Synthetic Chemical Factory".

January 1989

we set up "Linhai Xunqiao Synthetic Chemical Factory".